MARKET

CMPX

CMPX

Compass Therapeutics Inc
NASDAQ
2.070
-0.050
-2.36%
After Hours: 2.090 +0.02 +0.97% 19:34 07/24 EDT
OPEN
2.120
PREV CLOSE
2.120
HIGH
2.140
LOW
2.060
VOLUME
1.59M
TURNOVER
--
52 WEEK HIGH
6.88
52 WEEK LOW
1.610
MARKET CAP
372.78M
P/E (TTM)
-5.0304
1D
5D
1M
3M
1Y
5Y
1D
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Reuters · 3d ago
COMPASS THERAPEUTICS INC. <CMPX.O>: LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $4
Reuters · 4d ago
Weekly Report: what happened at CMPX last week (0713-0717)?
Weekly Report · 5d ago
Compass Therapeutics Abstract Accepted For Oral Presentation At Upcoming European Society For Medical Oncology Congress
Benzinga · 07/17 14:47
COMPASS THERAPEUTICS ANNOUNCES TOVECIMIG DATA ACCEPTED FOR AN ORAL PRESENTATION AT THE ESMO CONGRESS 2026
Reuters · 07/17 14:42
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity
Seeking Alpha · 07/15 18:31
Weekly Report: what happened at CMPX last week (0706-0710)?
Weekly Report · 07/13 10:13
Weekly Report: what happened at CMPX last week (0629-0703)?
Weekly Report · 07/06 10:17
More
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.

Webull offers Compass Therapeutics Inc. stock information, including NASDAQ: CMPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CMPX stock methods without spending real money on the virtual paper trading platform.